(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Opening Your True capacity: 12 Techniques for Personal growth - 2Figure out How to Introduce Sunlight powered chargers on Your Rooftop securely
- 3December's overlooked meteor shower peaks next week — will the Ursids surprise us?
- 4A Past filled with Old Civilizations: The World's Most established Societies
- 5Vote in favor of your Number one kind of juice
- 6 Home Cleaning Administrations to Keep Your Home Unblemished
- Southern Californians, your health insurance costs could rise in 2026
- Governors Ball 2026: Lorde, A$AP Rocky and Stray Kids set to headline
- Instructions to Safeguard Your Speculations In the midst of Changing Disc Rates
- 10 Work Valuable chances to Assist with supporting Your Advanced degree
- Manual for 6 Busssiness Class Flights
- Woman, 60, Is Finally Traveling the World Decades After Husband’s Death Held Her Back
- See the 'amazing' photos of Earth taken on historic Artemis II moon mission
- See as Your #1: These Low-Sugar Food sources You Ought to Attempt
